192 related articles for article (PubMed ID: 17938578)
21. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Paoluzzi L; Gonen M; Gardner JR; Mastrella J; Yang D; Holmlund J; Sorensen M; Leopold L; Manova K; Marcucci G; Heaney ML; O'Connor OA
Blood; 2008 Jun; 111(11):5350-8. PubMed ID: 18292288
[TBL] [Abstract][Full Text] [Related]
22. ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells.
Sun J; Li ZM; Hu ZY; Lin XB; Zhou NN; Xian LJ; Yang DJ; Jiang WQ
Anticancer Drugs; 2008 Nov; 19(10):967-74. PubMed ID: 18827561
[TBL] [Abstract][Full Text] [Related]
23. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
Vega MI; Jazirehi AR; Huerta-Yepez S; Bonavida B
J Immunol; 2005 Aug; 175(4):2174-83. PubMed ID: 16081784
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Wong FY; Liem N; Xie C; Yan FL; Wong WC; Wang L; Yong WP
PLoS One; 2012; 7(12):e50786. PubMed ID: 23226540
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-induced non-Hodgkin's lymphoma in a patient with Hodgkin's disease--a case report.
Burney IA; Malik IA
J Pak Med Assoc; 1996 Jan; 46(1):14-5. PubMed ID: 8830160
[No Abstract] [Full Text] [Related]
26. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells.
Ogretmen B; Safa AR
Int J Cancer; 1996 Sep; 67(5):608-14. PubMed ID: 8782646
[TBL] [Abstract][Full Text] [Related]
28. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
29. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
[TBL] [Abstract][Full Text] [Related]
31. Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.
Kiewe P; Thiel E
Ann Hematol; 2011 Jan; 90(1):109-10. PubMed ID: 20387065
[No Abstract] [Full Text] [Related]
32. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.
Natoli A; Lüpertz R; Merz C; Müller WW; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2013 Oct; 133(8):1945-54. PubMed ID: 23553437
[TBL] [Abstract][Full Text] [Related]
33. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
[TBL] [Abstract][Full Text] [Related]
35. -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro.
Macoska JA; Adsule S; Tantivejkul K; Wang S; Pienta KJ; Lee CT
Pharmacol Res; 2008; 58(5-6):323-31. PubMed ID: 18840529
[TBL] [Abstract][Full Text] [Related]
36. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
37. Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
Hu Y; Yagüe E; Zhao J; Wang L; Bai J; Yang Q; Pan T; Zhao H; Liu J; Zhang J
Cancer Lett; 2018 Jun; 423():47-59. PubMed ID: 29496539
[TBL] [Abstract][Full Text] [Related]
38. Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
Yoon JS; Hwang DW; Kim ES; Kim JS; Kim S; Chung HJ; Lee SK; Yi JH; Uhm J; Won YW; Park BB; Choi JH; Lee YY
Invest New Drugs; 2016 Feb; 34(1):1-14. PubMed ID: 26581399
[TBL] [Abstract][Full Text] [Related]
39. Effect of antineoplastic drugs on the expression of Bcl-2 and Bcl-xL genes in the feline T-cell leukemia cell line.
Sano J; Nagafuchi S; Yamazaki J; Oguma K; Kano R; Hasegawa A
Res Vet Sci; 2005 Dec; 79(3):197-201. PubMed ID: 15893350
[TBL] [Abstract][Full Text] [Related]
40. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
